Influence of Chemotherapy Regimen Combined Trastuzumab on LVEF in Innermongulia Breast Cancer Patients
-
摘要: 目的 通过随访内蒙古地区接受含曲妥珠单抗化疗方案的乳腺癌患者左室射血分数(left ventricular ejection fraction,LVEF)变化趋势,了解其对预测患者心脏毒性的临床意义。方法对2008年10月—2011年1月期间接受含曲妥珠单抗化疗方案的22例乳腺癌患者治疗基线,治疗期间直至治疗结束后12月时对LVEF变化趋势进行随访。结果接受曲妥珠单抗治疗12月时辅助治疗组LVEF下降5.5%,解救化疗组下降5.5%,下降水平≥10％有3例,占14%,但均未出现心前区不适、胸闷等症状,2例患者在完成曲妥珠单抗治疗12月后出现间歇发作心前区不适、胸闷症状,但LVEF值随访未见异常;结论临床随访显示以LVEF作为心脏功能监测指标,曲妥珠单抗无论联合辅助化疗还是解救化疗方案对患者均显示良好的安全性,但在早期预测患者心功能不全方面可能价值有限。Abstract: Objective To investigate the relationship between the variation of LVEF(left ventricular ejection fraction) and cardiotoxicity in Innermongulia breast cancer patients who received chemotherapy regimen combined trastuzumab. Methods Follow up the breast cancer patients′ LVEF at the interval 3 months from the first beginning of trastuzumab to the 12 months after the last dose of trastuzumab since October 2008 to December 2011. Results The LVEF level decreased 5.5% when finished trastuzumab treatment in both adjuvant chemotherapy group or salvage chemotherapy group. The LVEF level in 3 of the patients decreased more than 10% while had no any heart failure symptoms. Two patient developed palpitations after 12 months of trastuzumab treatment while had normal LVEF level. Conclusion From the results of LVEF change for the patients accepted trastuzumab treatment combined adjuvant chemotherapy or salvage chemotherapy, the treatment is safe to the patients. LVEF is a suitable parameter to evaluate the safety of the treatment method, while it′s value in predicting early cardiotoxicity is limited.
-
Key words:
- Trastuzumab /
- Breast cancer /
- Left ventricular ejection fraction
-
-
[1] Jiang ZF,Shao ZM,Xu BH.Experts guideline recommendations for human epidermal growth factor receptor 2 diagnosis and treatment in breast cancer[J].Zhonghua Zhong Liu Za Zhi,2010,32(2)：158-60.[江泽飞,邵志敏,徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识[J].中华肿瘤杂志,2010,32(2)：158-60.] [2] Li XL,Wang YQ.Trastuzumab-induced cardiotoxicity and strategies for prevention and treatment[J].Yao Wu Bu Liang Fan Ying Za Zhi,2009,11(4)：257-9.[李晓玲,王育琴.曲妥珠单抗心脏毒性及防治策略[J].药物不良反应杂志,2009,11(4)：257-9.] [3] Zhang XQ,Liu PX.Adverse reactions of targeted agents and their prevention and treatment in breast carcinoma[J].Guo Ji Zhong Liu Xue Za Zhi,2009,36(4):276-9.[张晓清,刘鹏熙.乳腺癌靶向治疗药物的不良反应及其防治[J].国际肿瘤学杂志,2009,36(4):276-9.] [4] Guglin M,Cutro R,Mishkin JD.Trastuzumab-inducedcardiomyopathy[J].J Card Fail,2008,14(5):437-44. [5] Guglin M,Hartlage G,Reynolds C,et al.Trastuzumab-induced cardiomyopathy:not as benign as it looks? A retrospective study[J].J Card Fail,2009,15(8):651-7. [6] Fuller SJ,Sivarajah K,Sugden PH.ErbB receptors,their ligands,and the consequences of their activation and inhibition in the myocardium[J].J Mol Cell Cardiol,2008,44(5):831-54. [7] Costa RB,Kurra G,Greenberg L,et al.Geyer CE.Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2- positive early breast cancer[J].Ann Oncol,2010,21(11):2153-60. [8] Tan-Chiu E,Yothers G,Romond E,et al.Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel,with or without trastuzumab as adjuvant therapy in node-positive,human epidermal growth factor receptor 2-overexpressing breast cancer:NSABPB-31[J].J Clin Oncol,2005,23(31):7811-9. [9] Guarneri V,Lenihan DJ,Valero V,et al.Long-term cardiac tolerability of trastuzumab in metastatic breast cancer:the M.D.Anderson Cancer Center experience[J].J Clin Oncol,2006,24(25):4107-15.
计量
- 文章访问数: 2927
- HTML全文浏览量: 32
- PDF下载量: 613
下载:
